您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > TAS-115
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
TAS-115
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
TAS-115图片
CAS NO:1190836-34-0
规格:98%
分子量:518.56
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议
20mg电议

产品介绍
TAS-115是一种有效的VEGFR和c-Met/HGFR抑制剂,能够抑制rVEGFR2和rMET的活性,IC50值分别为30和32nM。
CAS:1190836-34-0
分子式:C27H23FN4O4S
分子量:518.56
纯度:98%
存储:Store at -20°C

Background:

TAS-115 is a potent VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively.


TAS-115 is ATP antagonism with inhibition constant (Ki) values against rVEGFR2 and rMET of 12 and 39 nM, respectively. AS-115 inhibits the kinase activity of both VEGFR2 and MET and their signal-dependent cell growth as strongly as other known VEGFR or MET inhibitors. TAS-115 induces less damage in various normal cells than do other VEGFR inhibitors[1]. TAS-115 does not affect the growth of PC-9 or HCC827 cells at concentrations less than 10 μM; however, the combined use of TAS-115 with erlotinib reverses HGF-induced resistance in the cell lines in a concentration-dependent manner. TAS-115 inhibits VEGF production by cancer cells and endothelial proliferation[2].


TAS-115 (50 mg/kg/d) completely prevents tumor growth during the treatment period. TAS-115 (200 mg/kg/d) induces a 48% regression from the initial tumor volume in MET-amplified human cancer transplanted models. The estimated 50% effective dose (ED50) of TAS-115 in this model is 8 mg/kg/d. TAS-115 significantly prolongs survival of these mice when administered at doses of 50 or 200 mg/kg/d[1]. TAS-115 inhibits angiogenesis in PC-9/HGF tumors in vivo. Moreover, the doublet erlotinib and TAS-115 successfully inhibit PC-9/HGF tumor growth and delay tumor regrowth associated with sustained tumor vasculature inhibition even after cessation of the treatment[2].


[1]. Fujita H, et al. The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile. Mol Cancer Ther. 2013 Dec;12(12):2685-96. [2]. Nakade J, et al. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation. J Thorac Oncol. 2014 Jun;9(6):775-83.